Mesothelioma Research Gets $3.58 Million Boost At Hawaii Cancer Center
Research & Clinical TrialsAsbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
Testimonials
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
APA
Povtak, T. (2020, October 16). Mesothelioma Research Gets $3.58 Million Boost At Hawaii Cancer Center. Asbestos.com. Retrieved February 8, 2023, from https://www.asbestos.com/news/2011/06/23/mesothelioma-research-gets-3million-donation/
MLA
Povtak, Tim. "Mesothelioma Research Gets $3.58 Million Boost At Hawaii Cancer Center." Asbestos.com, 16 Oct 2020, https://www.asbestos.com/news/2011/06/23/mesothelioma-research-gets-3million-donation/.
Chicago
Povtak, Tim. "Mesothelioma Research Gets $3.58 Million Boost At Hawaii Cancer Center." Asbestos.com. Last modified October 16, 2020. https://www.asbestos.com/news/2011/06/23/mesothelioma-research-gets-3million-donation/.

Dr. Michele Carbone at the University of Hawaii Cancer Center has been renowned the past several years as one of the world’s leaders in the fight against asbestos cancer.
This will only make him better.
The Cancer Center announced Wednesday a $3.58 million donation designated specifically for mesothelioma research, Carbone’s specialty. It is the second-largest donation in the UH Cancer Center’s history.
“This gift is critical to support our efforts to generate discoveries that will aid in the prevention of mesothelioma and the development of new therapies,” Carbone said. “This will solidify Hawaii as the leading place in the research of mesothelioma.”
Mesothelioma has no known cure and a five-year survival rate of 10 percent. There are 2,000 to 3,000 patients diagnosed in the United States each year. The cancer is considerably worse in other parts of the world, particularly where asbestos still is less regulated.
Carbone has spent parts of the past 15 years studying a region in Turkey, where nearly 50 percent of its residents have died from the disease. His study attracted considerable attention worldwide.
He has been at the University of Hawaii since 2006, first as director of thoracic oncology and then as the director of the cancer center.
“We’re proud that Dr. Carbone’s team is leading the world in this area of discovery. Mesothelioma is a serious public-health problem,” said Virginia Hinshaw, chancellor at the University of Hawaii Manoa. “This gift validates their efforts and will help them remain at the forefront of thoracic oncology research.”
Carbone and his team are in the midst of a clinical trial sponsored by the Early Detection Research Network of the U.S. National Cancer Institute. Early detection is critical, but particularly troublesome, with this cancer, which has a latency period of up to 50 years. It usually is not detected until the later stages, which makes the survival rate so low.